Sugi Predict

Sugi Predict / Targets / APOBEC3B

APOBEC3B

DNA dC->dU-editing enzyme APOBEC-3B · Q9UH17 · APOBEC3B on Sugi Atlas →

127 patent compounds predicted against APOBEC3B, 103 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16907871 SCHEMBL16907871 0.76 5/20
SCHEMBL22731822 SCHEMBL22731822 0.42 4/20
SCHEMBL18762150 SCHEMBL18762150 0.65 2/20
SCHEMBL18292329 SCHEMBL18292329 0.64 2/20
SCHEMBL1898606 SCHEMBL1898606 0.61 2/20
SCHEMBL17318624 SCHEMBL17318624 0.61 2/20
SCHEMBL17318598 SCHEMBL17318598 0.60 2/20
SCHEMBL1899898 SCHEMBL1899898 0.56 2/20
SCHEMBL1901858 SCHEMBL1901858 0.52 2/20
SCHEMBL15709584 SCHEMBL15709584 0.52 2/20
SCHEMBL30919334 SCHEMBL30919334 0.52 2/20
SCHEMBL15731906 SCHEMBL15731906 0.51 2/20
SCHEMBL15730826 SCHEMBL15730826 0.49 2/20
SCHEMBL1898383 SCHEMBL1898383 0.77 1/20
SCHEMBL1898854 SCHEMBL1898854 0.67 1/20
SCHEMBL1901215 SCHEMBL1901215 0.66 1/20
SCHEMBL17318607 SCHEMBL17318607 0.66 1/20
SCHEMBL17318576 SCHEMBL17318576 0.65 1/20
SCHEMBL13357696 SCHEMBL13357696 0.65 1/20
SCHEMBL18762173 SCHEMBL18762173 0.65 1/20

Clinical trials — most relevant to APOBEC3B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS PHASE4COMPLETED
Efficacy of Adaptogens in Patients With Long COVID-19 PHASE2/PHASE3COMPLETED
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Gene Therapy for ADA-SCID PHASE1/PHASE2COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer PHASE2RECRUITING
Surgical Pembro +/- Olaparib w TMZ for rGBM PHASE2RECRUITING
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector PHASE1COMPLETED
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors PHASE1COMPLETED
ADAR1 Expression Level in Rectal Cancer nanRECRUITING
COsegregation of VARiants in Panel of Genes nanRECRUITING
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA) nanUNKNOWN
Natural History of Autosomal Dominant Hearing Loss nanRECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates nanCOMPLETED
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) nanRECRUITING
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) nanUNKNOWN
Endocrine Disruptors and Life STILe in Breast Cancer Development nanUNKNOWN
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise nanRECRUITING
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation nanRECRUITING
Myeloid Cells in Patients With Covid-19 Pneumonia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a APOBEC3B binder may also engage these)

ProteinNameSimilarity
APOBEC3G DNA dC->dU-editing enzyme APOBEC-3G 0.999 landscape →
Q694C1 — 0.998 Q694C1 →
Q694B9 — 0.998 Q694B9 →
Q8IUX4 — 0.998 Q8IUX4 →
Q7YR23 — 0.998 Q7YR23 →
Q694B8 — 0.997 Q694B8 →
Q694B6 — 0.997 Q694B6 →
Q7YR25 — 0.996 Q7YR25 →
Q694B7 — 0.996 Q694B7 →
Q694B5 — 0.996 Q694B5 →
Q7YR24 — 0.996 Q7YR24 →
Q694C4 — 0.995 Q694C4 →
Q96AK3 — 0.994 Q96AK3 →
Q694C5 — 0.994 Q694C5 →
Q694C0 — 0.993 Q694C0 →
Q694C2 — 0.992 Q694C2 →
Q4VDN5 — 0.992 Q4VDN5 →
APOBEC3A DNA dC->dU-editing enzyme APOBEC-3A 0.990 landscape →
APOBEC3C DNA dC->dU-editing enzyme APOBEC-3C 0.990 landscape →
Q9GZX7 — 0.989 Q9GZX7 →
P60705 — 0.988 P60705 →
Q75W64 — 0.987 Q75W64 →
Q1WBT4 — 0.987 Q1WBT4 →
Q2PT36 — 0.985 Q2PT36 →
Q9WVE0 — 0.982 Q9WVE0 →
Q6NTF7 — 0.982 Q6NTF7 →
Q99J72 — 0.982 Q99J72 →
P60704 — 0.981 P60704 →
A9QA56 — 0.980 A9QA56 →
Q19Q52 — 0.975 Q19Q52 →